Scotiabank Boosts Aura Biosciences (NASDAQ:AURA) Price Target to $23.00

Aura Biosciences (NASDAQ:AURA) had its price objective upped by Scotiabank from $20.00 to $23.00 in a research note released on Friday, Marketbeat reports. The brokerage currently has a sector outperform rating on the stock.

Several other equities research analysts have also recently commented on the stock. BTIG Research lifted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research report on Friday. HC Wainwright increased their price target on Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Friday. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. JMP Securities raised their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a report on Friday, September 13th. Finally, Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Aura Biosciences currently has a consensus rating of “Buy” and an average price target of $23.00.

Aura Biosciences Price Performance

AURA stock opened at $11.74 on Friday. The company has a 50 day moving average price of $8.66 and a 200 day moving average price of $8.07. Aura Biosciences has a fifty-two week low of $5.99 and a fifty-two week high of $12.38. The stock has a market capitalization of $581.63 million, a PE ratio of -6.31 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. As a group, equities analysts expect that Aura Biosciences will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Aura Biosciences

In other news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares in the company, valued at $1,193,150.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider Los Pinos Elisabet De sold 24,992 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $12.04, for a total transaction of $300,903.68. Following the sale, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CTO Mark Plavsic sold 7,383 shares of the stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now directly owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 5.40% of the stock is owned by insiders.

Institutional Trading of Aura Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in AURA. American Century Companies Inc. bought a new position in Aura Biosciences during the second quarter worth about $119,000. American International Group Inc. grew its position in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after purchasing an additional 3,782 shares during the last quarter. Virtu Financial LLC bought a new position in Aura Biosciences during the 1st quarter worth $144,000. SG Americas Securities LLC bought a new position in Aura Biosciences during the third quarter worth about $169,000. Finally, Rhumbline Advisers raised its position in shares of Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares in the last quarter. 96.75% of the stock is owned by institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.